First Horizon Advisors Inc. Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

First Horizon Advisors Inc. lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 38.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 484 shares of the medical equipment provider’s stock after buying an additional 134 shares during the period. First Horizon Advisors Inc.’s holdings in Hologic were worth $39,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Innealta Capital LLC purchased a new stake in Hologic during the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the third quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic during the first quarter worth about $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC increased its holdings in Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Hologic stock opened at $79.73 on Tuesday. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $18.52 billion, a P/E ratio of 23.94, a PEG ratio of 2.49 and a beta of 0.98. The stock’s 50 day moving average is $80.38 and its 200 day moving average is $78.38.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the company earned $0.89 earnings per share. On average, equities research analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. UBS Group lifted their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. JPMorgan Chase & Co. raised their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.